2019 Joint Commission National Patient Safety Goals: Update and Practical Advice

Understand the update of the National Patient Safety Goals to be sure your organization is in compliance with the requirements. Each year healthcare providers must meet the requirements of the Joint Commission's National Patient Safety Goals as part of the accreditation process. Receive an overview and update of the 2019 National Patient Safety Goals. Receive practical advice to implement the goals. Failing to meet a requirement will result in a requirement for improvement. This information is critical to ensure you are aware of the requirements.
Watch Now

Spotlight

OTHER ON-DEMAND WEBINARS

Simplifying ChIP from Primary Cells and Clinical Samples for Epigenetic Applications

Biocompare

Mapping the epigenetic and transcription factor landscape is essential for understanding gene regulatory mechanisms and holds huge potential for identification of biomarkers and targets for epigenetic therapy.
Watch Now

PREPARE YOUR ENTERPRISE CLOUD STRATEGY FOR 2019: 7 THINGS TO THINK ABOUT NOW

flexerasoftware

Cloud adoption just keeps on growing and now is the time to take control. Your enterprise cloud strategy for 2019 needs to address the broad impact of cloud use in your company. Your strategy should also cover implications for your technical processes, as well as supporting areas including finance, governance, organization, and culture.
Watch Now

Is Your Biotherapeutic Immunomodulatory? How to Use Immunoassays to Get the Right Answer

Immuni T

Biotherapeutics are a class of large medicinal products that are being increasingly used for various medical applications including vaccination, therapeutic drug delivery systems and the treatment of human diseases. Biotherapeutics offer the advantages of increased specificity and reduced toxicity compared to small molecules. However, they can inappropriately activate the immune system. This potential biotherapeutics-mediated immunogenicity must be assessed as early as possible during drug development since it can be the cause of serious events such as autoimmunity, inflammation, anti-drug antibodies (ADAs) production, hypersensitivity reactions (allergenicity) or cytokine storm syndrome. Moreover, since biotherapeutics are produced using biological means, the development of biosimilars must include comparative immunogenicity and biological assay testings.
Watch Now

Novel Bioassays in Picodroplets for Single Cell Analysis

Using microfluidic devices with well-defined microchannel geometries and accurate flow control, uniform pico-litre volume droplets (picodroplets) can be generated and used as miniaturized “test tubes” for high-throughput bioassays.
Watch Now

Spotlight

resources